ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Value-added Medicines (VAM) Development Service Market Research Report 2026
Published Date: 2026-01-22
|
Report Code: QYRE-Auto-9G18992
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Value added Medicines VAM Development Service Market Research Report 2025
BUY CHAPTERS

Global Value-added Medicines (VAM) Development Service Market Research Report 2026

Code: QYRE-Auto-9G18992
Report
2026-01-22
Pages:109
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
TIEFENBACHER GROUP
Hyloris Pharmaceuticals SA
Adamed
Colonis
Towa International
Sandoz Inc
Adragos Pharma
Altus Drug Development
Galenicap

Value-added Medicines (VAM) Development Service Market Size

The global Value-added Medicines (VAM) Development Service market was valued at US$ 638 million in 2025 and is anticipated to reach US$ 1269 million by 2032, at a CAGR of 10.5% from 2026 to 2032.

Value-added Medicines (VAM) Development Service Market

Value-added Medicines (VAM) Development Service Market

Value-added Medicines Developmen‌t‌ Service usually refers to adding additional value to pharmaceutical products by providing professional technical support, innovative solutions and optimized processes in the drug development and manufacturing process. These services may include the design, synthesis, analysis, optimization, production, quality control and other aspects of drug development to improve drug efficacy, safety, production efficiency and patient experience.
The North American market for Value-added Medicines (VAM) Development Service is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Value-added Medicines (VAM) Development Service is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The global market for Value-added Medicines (VAM) Development Service in Pharmaceutical Companies is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.
Major global companies of Value-added Medicines (VAM) Development Service include Altus Drug Development, TIEFENBACHER GROUP, Hyloris Pharmaceuticals SA, Adamed, Colonis, Towa International, Galenicap, Sandoz AG, Adragos Pharma, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Value-added Medicines (VAM) Development Service market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Value-added Medicines (VAM) Development Service. The Value-added Medicines (VAM) Development Service market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Value-added Medicines (VAM) Development Service market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Value-added Medicines (VAM) Development Service manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Value-added Medicines (VAM) Development Service Market Report

Report Metric Details
Report Name Value-added Medicines (VAM) Development Service Market
Accounted market size in 2025 US$ 638 in million
Forecasted market size in 2032 US$ 1269 million
CAGR 10.5%
Base Year 2025
Forecasted years 2026 - 2032
Segment by Type
  • Chronic Disease Treatment Drugs
  • Infectious Disease Treatment Drugs
  • Tumor Treatment Drugs
  • Other
Segment by Application
  • Pharmaceutical Companies
  • Biotech Companies
  • Hospitals and Medical Institutions
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Altus Drug Development, TIEFENBACHER GROUP, Hyloris Pharmaceuticals SA, Adamed, Colonis, Towa International, Galenicap, Sandoz AG, Adragos Pharma
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
  • Chapter 3: Provides a detailed view of the competitive landscape for Value-added Medicines (VAM) Development Service companies, covering revenue share, development plans, and mergers and acquisitions.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
  • Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
  • Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
  • Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
  • Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is Value-added Medicines (VAM) Development Service Market growing?

Ans: The Value-added Medicines (VAM) Development Service Market witnessing a CAGR of 10.5% during the forecast period 2026-2032.

What is the Value-added Medicines (VAM) Development Service Market size in 2032?

Ans: The Value-added Medicines (VAM) Development Service Market size in 2032 will be US$ 1269 million.

Who are the main players in the Value-added Medicines (VAM) Development Service Market report?

Ans: The main players in the Value-added Medicines (VAM) Development Service Market are Altus Drug Development, TIEFENBACHER GROUP, Hyloris Pharmaceuticals SA, Adamed, Colonis, Towa International, Galenicap, Sandoz AG, Adragos Pharma

What are the Application segmentation covered in the Value-added Medicines (VAM) Development Service Market report?

Ans: The Applications covered in the Value-added Medicines (VAM) Development Service Market report are Pharmaceutical Companies, Biotech Companies, Hospitals and Medical Institutions

What are the Type segmentation covered in the Value-added Medicines (VAM) Development Service Market report?

Ans: The Types covered in the Value-added Medicines (VAM) Development Service Market report are Chronic Disease Treatment Drugs, Infectious Disease Treatment Drugs, Tumor Treatment Drugs, Other

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Value-added Medicines (VAM) Development Service Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Chronic Disease Treatment Drugs
1.2.3 Infectious Disease Treatment Drugs
1.2.4 Tumor Treatment Drugs
1.2.5 Other
1.3 Market by Application
1.3.1 Global Value-added Medicines (VAM) Development Service Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Pharmaceutical Companies
1.3.3 Biotech Companies
1.3.4 Hospitals and Medical Institutions
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Value-added Medicines (VAM) Development Service Market Perspective (2021–2032)
2.2 Global Value-added Medicines (VAM) Development Service Growth Trends by Region
2.2.1 Global Value-added Medicines (VAM) Development Service Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Value-added Medicines (VAM) Development Service Historic Market Size by Region (2021–2026)
2.2.3 Value-added Medicines (VAM) Development Service Forecasted Market Size by Region (2027–2032)
2.3 Value-added Medicines (VAM) Development Service Market Dynamics
2.3.1 Value-added Medicines (VAM) Development Service Industry Trends
2.3.2 Value-added Medicines (VAM) Development Service Market Drivers
2.3.3 Value-added Medicines (VAM) Development Service Market Challenges
2.3.4 Value-added Medicines (VAM) Development Service Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Value-added Medicines (VAM) Development Service Players by Revenue
3.1.1 Global Top Value-added Medicines (VAM) Development Service Players by Revenue (2021–2026)
3.1.2 Global Value-added Medicines (VAM) Development Service Revenue Market Share by Players (2021–2026)
3.2 Global Top Value-added Medicines (VAM) Development Service Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Value-added Medicines (VAM) Development Service Revenue
3.4 Global Value-added Medicines (VAM) Development Service Market Concentration Ratio
3.4.1 Global Value-added Medicines (VAM) Development Service Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Value-added Medicines (VAM) Development Service Revenue in 2025
3.5 Global Key Players of Value-added Medicines (VAM) Development Service Head Offices and Areas Served
3.6 Global Key Players of Value-added Medicines (VAM) Development Service, Products and Applications
3.7 Global Key Players of Value-added Medicines (VAM) Development Service, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Value-added Medicines (VAM) Development Service Breakdown Data by Type
4.1 Global Value-added Medicines (VAM) Development Service Historic Market Size by Type (2021–2026)
4.2 Global Value-added Medicines (VAM) Development Service Forecasted Market Size by Type (2027–2032)
5 Value-added Medicines (VAM) Development Service Breakdown Data by Application
5.1 Global Value-added Medicines (VAM) Development Service Historic Market Size by Application (2021–2026)
5.2 Global Value-added Medicines (VAM) Development Service Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Value-added Medicines (VAM) Development Service Market Size (2021–2032)
6.2 North America Value-added Medicines (VAM) Development Service Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Value-added Medicines (VAM) Development Service Market Size by Country (2021–2026)
6.4 North America Value-added Medicines (VAM) Development Service Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Value-added Medicines (VAM) Development Service Market Size (2021–2032)
7.2 Europe Value-added Medicines (VAM) Development Service Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Value-added Medicines (VAM) Development Service Market Size by Country (2021–2026)
7.4 Europe Value-added Medicines (VAM) Development Service Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Value-added Medicines (VAM) Development Service Market Size (2021–2032)
8.2 Asia-Pacific Value-added Medicines (VAM) Development Service Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Value-added Medicines (VAM) Development Service Market Size by Region (2021–2026)
8.4 Asia-Pacific Value-added Medicines (VAM) Development Service Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Value-added Medicines (VAM) Development Service Market Size (2021–2032)
9.2 Latin America Value-added Medicines (VAM) Development Service Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Value-added Medicines (VAM) Development Service Market Size by Country (2021–2026)
9.4 Latin America Value-added Medicines (VAM) Development Service Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Value-added Medicines (VAM) Development Service Market Size (2021–2032)
10.2 Middle East & Africa Value-added Medicines (VAM) Development Service Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Value-added Medicines (VAM) Development Service Market Size by Country (2021–2026)
10.4 Middle East & Africa Value-added Medicines (VAM) Development Service Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Altus Drug Development
11.1.1 Altus Drug Development Company Details
11.1.2 Altus Drug Development Business Overview
11.1.3 Altus Drug Development Value-added Medicines (VAM) Development Service Introduction
11.1.4 Altus Drug Development Revenue in Value-added Medicines (VAM) Development Service Business (2021–2026)
11.1.5 Altus Drug Development Recent Development
11.2 TIEFENBACHER GROUP
11.2.1 TIEFENBACHER GROUP Company Details
11.2.2 TIEFENBACHER GROUP Business Overview
11.2.3 TIEFENBACHER GROUP Value-added Medicines (VAM) Development Service Introduction
11.2.4 TIEFENBACHER GROUP Revenue in Value-added Medicines (VAM) Development Service Business (2021–2026)
11.2.5 TIEFENBACHER GROUP Recent Development
11.3 Hyloris Pharmaceuticals SA
11.3.1 Hyloris Pharmaceuticals SA Company Details
11.3.2 Hyloris Pharmaceuticals SA Business Overview
11.3.3 Hyloris Pharmaceuticals SA Value-added Medicines (VAM) Development Service Introduction
11.3.4 Hyloris Pharmaceuticals SA Revenue in Value-added Medicines (VAM) Development Service Business (2021–2026)
11.3.5 Hyloris Pharmaceuticals SA Recent Development
11.4 Adamed
11.4.1 Adamed Company Details
11.4.2 Adamed Business Overview
11.4.3 Adamed Value-added Medicines (VAM) Development Service Introduction
11.4.4 Adamed Revenue in Value-added Medicines (VAM) Development Service Business (2021–2026)
11.4.5 Adamed Recent Development
11.5 Colonis
11.5.1 Colonis Company Details
11.5.2 Colonis Business Overview
11.5.3 Colonis Value-added Medicines (VAM) Development Service Introduction
11.5.4 Colonis Revenue in Value-added Medicines (VAM) Development Service Business (2021–2026)
11.5.5 Colonis Recent Development
11.6 Towa International
11.6.1 Towa International Company Details
11.6.2 Towa International Business Overview
11.6.3 Towa International Value-added Medicines (VAM) Development Service Introduction
11.6.4 Towa International Revenue in Value-added Medicines (VAM) Development Service Business (2021–2026)
11.6.5 Towa International Recent Development
11.7 Galenicap
11.7.1 Galenicap Company Details
11.7.2 Galenicap Business Overview
11.7.3 Galenicap Value-added Medicines (VAM) Development Service Introduction
11.7.4 Galenicap Revenue in Value-added Medicines (VAM) Development Service Business (2021–2026)
11.7.5 Galenicap Recent Development
11.8 Sandoz AG
11.8.1 Sandoz AG Company Details
11.8.2 Sandoz AG Business Overview
11.8.3 Sandoz AG Value-added Medicines (VAM) Development Service Introduction
11.8.4 Sandoz AG Revenue in Value-added Medicines (VAM) Development Service Business (2021–2026)
11.8.5 Sandoz AG Recent Development
11.9 Adragos Pharma
11.9.1 Adragos Pharma Company Details
11.9.2 Adragos Pharma Business Overview
11.9.3 Adragos Pharma Value-added Medicines (VAM) Development Service Introduction
11.9.4 Adragos Pharma Revenue in Value-added Medicines (VAM) Development Service Business (2021–2026)
11.9.5 Adragos Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
TIEFENBACHER GROUP
Hyloris Pharmaceuticals SA
Adamed
Colonis
Towa International
Sandoz Inc
Adragos Pharma
Altus Drug Development
Galenicap
List of Tables
 Table 1. Global Value-added Medicines (VAM) Development Service Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
 Table 2. Key Players of Chronic Disease Treatment Drugs
 Table 3. Key Players of Infectious Disease Treatment Drugs
 Table 4. Key Players of Tumor Treatment Drugs
 Table 5. Key Players of Other
 Table 6. Global Value-added Medicines (VAM) Development Service Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
 Table 7. Global Value-added Medicines (VAM) Development Service Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 8. Global Value-added Medicines (VAM) Development Service Market Size by Region (US$ Million), 2021–2026
 Table 9. Global Value-added Medicines (VAM) Development Service Market Share by Region (2021–2026)
 Table 10. Global Value-added Medicines (VAM) Development Service Forecasted Market Size by Region (US$ Million), 2027–2032
 Table 11. Global Value-added Medicines (VAM) Development Service Market Share by Region (2027–2032)
 Table 12. Value-added Medicines (VAM) Development Service Market Trends
 Table 13. Value-added Medicines (VAM) Development Service Market Drivers
 Table 14. Value-added Medicines (VAM) Development Service Market Challenges
 Table 15. Value-added Medicines (VAM) Development Service Market Restraints
 Table 16. Global Value-added Medicines (VAM) Development Service Revenue by Players (US$ Million), 2021–2026
 Table 17. Global Value-added Medicines (VAM) Development Service Market Share by Players (2021–2026)
 Table 18. Global Top Value-added Medicines (VAM) Development Service Players by Tier (Tier 1, Tier 2, and Tier 3), based on Value-added Medicines (VAM) Development Service Revenue, 2025
 Table 19. Ranking of Global Top Value-added Medicines (VAM) Development Service Companies by Revenue (US$ Million) in 2025
 Table 20. Global 5 Largest Players Market Share by Value-added Medicines (VAM) Development Service Revenue (CR5 and HHI), 2021–2026
 Table 21. Global Key Players of Value-added Medicines (VAM) Development Service, Headquarters and Area Served
 Table 22. Global Key Players of Value-added Medicines (VAM) Development Service, Products and Applications
 Table 23. Global Key Players of Value-added Medicines (VAM) Development Service, Date of General Availability (GA)
 Table 24. Mergers and Acquisitions, Expansion Plans
 Table 25. Global Value-added Medicines (VAM) Development Service Market Size by Type (US$ Million), 2021–2026
 Table 26. Global Value-added Medicines (VAM) Development Service Revenue Market Share by Type (2021–2026)
 Table 27. Global Value-added Medicines (VAM) Development Service Forecasted Market Size by Type (US$ Million), 2027–2032
 Table 28. Global Value-added Medicines (VAM) Development Service Revenue Market Share by Type (2027–2032)
 Table 29. Global Value-added Medicines (VAM) Development Service Market Size by Application (US$ Million), 2021–2026
 Table 30. Global Value-added Medicines (VAM) Development Service Revenue Market Share by Application (2021–2026)
 Table 31. Global Value-added Medicines (VAM) Development Service Forecasted Market Size by Application (US$ Million), 2027–2032
 Table 32. Global Value-added Medicines (VAM) Development Service Revenue Market Share by Application (2027–2032)
 Table 33. North America Value-added Medicines (VAM) Development Service Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 34. North America Value-added Medicines (VAM) Development Service Market Size by Country (US$ Million), 2021–2026
 Table 35. North America Value-added Medicines (VAM) Development Service Market Size by Country (US$ Million), 2027–2032
 Table 36. Europe Value-added Medicines (VAM) Development Service Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 37. Europe Value-added Medicines (VAM) Development Service Market Size by Country (US$ Million), 2021–2026
 Table 38. Europe Value-added Medicines (VAM) Development Service Market Size by Country (US$ Million), 2027–2032
 Table 39. Asia-Pacific Value-added Medicines (VAM) Development Service Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 40. Asia-Pacific Value-added Medicines (VAM) Development Service Market Size by Region (US$ Million), 2021–2026
 Table 41. Asia-Pacific Value-added Medicines (VAM) Development Service Market Size by Region (US$ Million), 2027–2032
 Table 42. Latin America Value-added Medicines (VAM) Development Service Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 43. Latin America Value-added Medicines (VAM) Development Service Market Size by Country (US$ Million), 2021–2026
 Table 44. Latin America Value-added Medicines (VAM) Development Service Market Size by Country (US$ Million), 2027–2032
 Table 45. Middle East & Africa Value-added Medicines (VAM) Development Service Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 46. Middle East & Africa Value-added Medicines (VAM) Development Service Market Size by Country (US$ Million), 2021–2026
 Table 47. Middle East & Africa Value-added Medicines (VAM) Development Service Market Size by Country (US$ Million), 2027–2032
 Table 48. Altus Drug Development Company Details
 Table 49. Altus Drug Development Business Overview
 Table 50. Altus Drug Development Value-added Medicines (VAM) Development Service Product
 Table 51. Altus Drug Development Revenue in Value-added Medicines (VAM) Development Service Business (US$ Million), 2021–2026
 Table 52. Altus Drug Development Recent Development
 Table 53. TIEFENBACHER GROUP Company Details
 Table 54. TIEFENBACHER GROUP Business Overview
 Table 55. TIEFENBACHER GROUP Value-added Medicines (VAM) Development Service Product
 Table 56. TIEFENBACHER GROUP Revenue in Value-added Medicines (VAM) Development Service Business (US$ Million), 2021–2026
 Table 57. TIEFENBACHER GROUP Recent Development
 Table 58. Hyloris Pharmaceuticals SA Company Details
 Table 59. Hyloris Pharmaceuticals SA Business Overview
 Table 60. Hyloris Pharmaceuticals SA Value-added Medicines (VAM) Development Service Product
 Table 61. Hyloris Pharmaceuticals SA Revenue in Value-added Medicines (VAM) Development Service Business (US$ Million), 2021–2026
 Table 62. Hyloris Pharmaceuticals SA Recent Development
 Table 63. Adamed Company Details
 Table 64. Adamed Business Overview
 Table 65. Adamed Value-added Medicines (VAM) Development Service Product
 Table 66. Adamed Revenue in Value-added Medicines (VAM) Development Service Business (US$ Million), 2021–2026
 Table 67. Adamed Recent Development
 Table 68. Colonis Company Details
 Table 69. Colonis Business Overview
 Table 70. Colonis Value-added Medicines (VAM) Development Service Product
 Table 71. Colonis Revenue in Value-added Medicines (VAM) Development Service Business (US$ Million), 2021–2026
 Table 72. Colonis Recent Development
 Table 73. Towa International Company Details
 Table 74. Towa International Business Overview
 Table 75. Towa International Value-added Medicines (VAM) Development Service Product
 Table 76. Towa International Revenue in Value-added Medicines (VAM) Development Service Business (US$ Million), 2021–2026
 Table 77. Towa International Recent Development
 Table 78. Galenicap Company Details
 Table 79. Galenicap Business Overview
 Table 80. Galenicap Value-added Medicines (VAM) Development Service Product
 Table 81. Galenicap Revenue in Value-added Medicines (VAM) Development Service Business (US$ Million), 2021–2026
 Table 82. Galenicap Recent Development
 Table 83. Sandoz AG Company Details
 Table 84. Sandoz AG Business Overview
 Table 85. Sandoz AG Value-added Medicines (VAM) Development Service Product
 Table 86. Sandoz AG Revenue in Value-added Medicines (VAM) Development Service Business (US$ Million), 2021–2026
 Table 87. Sandoz AG Recent Development
 Table 88. Adragos Pharma Company Details
 Table 89. Adragos Pharma Business Overview
 Table 90. Adragos Pharma Value-added Medicines (VAM) Development Service Product
 Table 91. Adragos Pharma Revenue in Value-added Medicines (VAM) Development Service Business (US$ Million), 2021–2026
 Table 92. Adragos Pharma Recent Development
 Table 93. Research Programs/Design for This Report
 Table 94. Key Data Information from Secondary Sources
 Table 95. Key Data Information from Primary Sources
 Table 96. Authors List of This Report


List of Figures
 Figure 1. Value-added Medicines (VAM) Development Service Picture
 Figure 2. Global Value-added Medicines (VAM) Development Service Market Size Comparison by Type (US$ Million), 2021–2032
 Figure 3. Global Value-added Medicines (VAM) Development Service Market Share by Type: 2025 vs 2032
 Figure 4. Chronic Disease Treatment Drugs Features
 Figure 5. Infectious Disease Treatment Drugs Features
 Figure 6. Tumor Treatment Drugs Features
 Figure 7. Other Features
 Figure 8. Global Value-added Medicines (VAM) Development Service Market Size by Application (US$ Million), 2021–2032
 Figure 9. Global Value-added Medicines (VAM) Development Service Market Share by Application: 2025 vs 2032
 Figure 10. Pharmaceutical Companies Case Studies
 Figure 11. Biotech Companies Case Studies
 Figure 12. Hospitals and Medical Institutions Case Studies
 Figure 13. Value-added Medicines (VAM) Development Service Report Years Considered
 Figure 14. Global Value-added Medicines (VAM) Development Service Market Size (US$ Million), Year-over-Year: 2021–2032
 Figure 15. Global Value-added Medicines (VAM) Development Service Market Size, (US$ Million), 2021 vs 2025 vs 2032
 Figure 16. Global Value-added Medicines (VAM) Development Service Market Share by Region: 2025 vs 2032
 Figure 17. Global Value-added Medicines (VAM) Development Service Market Share by Players in 2025
 Figure 18. Global Value-added Medicines (VAM) Development Service Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
 Figure 19. The Top 10 and 5 Players Market Share by Value-added Medicines (VAM) Development Service Revenue in 2025
 Figure 20. North America Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 21. North America Value-added Medicines (VAM) Development Service Market Share by Country (2021–2032)
 Figure 22. United States Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 23. Canada Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 24. Europe Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 25. Europe Value-added Medicines (VAM) Development Service Market Share by Country (2021–2032)
 Figure 26. Germany Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 27. France Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 28. U.K. Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 29. Italy Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 30. Russia Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 31. Ireland Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 32. Asia-Pacific Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 33. Asia-Pacific Value-added Medicines (VAM) Development Service Market Share by Region (2021–2032)
 Figure 34. China Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 35. Japan Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 36. South Korea Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 37. Southeast Asia Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 38. India Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 39. Australia & New Zealand Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 40. Latin America Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 41. Latin America Value-added Medicines (VAM) Development Service Market Share by Country (2021–2032)
 Figure 42. Mexico Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 43. Brazil Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 44. Middle East & Africa Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 45. Middle East & Africa Value-added Medicines (VAM) Development Service Market Share by Country (2021–2032)
 Figure 46. Israel Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 47. Saudi Arabia Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 48. UAE Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
 Figure 49. Altus Drug Development Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2021–2026)
 Figure 50. TIEFENBACHER GROUP Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2021–2026)
 Figure 51. Hyloris Pharmaceuticals SA Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2021–2026)
 Figure 52. Adamed Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2021–2026)
 Figure 53. Colonis Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2021–2026)
 Figure 54. Towa International Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2021–2026)
 Figure 55. Galenicap Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2021–2026)
 Figure 56. Sandoz AG Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2021–2026)
 Figure 57. Adragos Pharma Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2021–2026)
 Figure 58. Bottom-up and Top-down Approaches for This Report
 Figure 59. Data Triangulation
 Figure 60. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

Global Nanomedicine Development and Manufacturing Services Market Research Report 2025
Global Commercial Drug Manufacturing Service Market Research Report 2025
Global Dosage Form Development Service Market Research Report 2025
Global Generic Drug Research and Development Services Market Research Report 2024
Global mRNA Vaccine Drugs Development Services Market Research Report 2024
Global Vaccine Development Service Market Research Report 2025
Global Drug Particle Engineering Service Market Research Report 2025
Global Antibody Development Services Market Research Report 2025
Global Antibody Drug CDMO Service Market Research Report 2024
Drug Discovery and Development Services Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Pharmaceutical Analytical Service Market Research Report 2025
Global mRNA Development and Manufacturing Services Market Research Report 2025
Global Pharmaceutical Characterization Service Market Research Report 2025
Global Value Added Services VAS in Retail Market Research Report 2024
Global Value added Medicines VAM Market Research Report 2025
Global Mobile Value Added Services MVAS Market Research Report 2024
Global Small Molecule Drug CDMO Services Market Research Report 2024
Global API Drug Development Service Market Research Report 2024
Global Pharmaceutical Formulation Development Market Research Report 2025
Global GNSS Value added Service Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions